Australia markets close in 1 hour 41 minutes

Cisen Pharmaceutical Co., Ltd. (603367.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
14.69-0.08 (-0.54%)
As of 11:29AM CST. Market open.
Currency in CNY

Valuation measures4

Market cap (intra-day) 6.69B
Enterprise value 4.31B
Trailing P/E 14.92
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.53
Price/book (mrq)1.20
Enterprise value/revenue 0.99
Enterprise value/EBITDA 8.76

Trading information

Stock price history

Beta (5Y monthly) 0.20
52-week change 30.61%
S&P500 52-week change 321.23%
52-week high 316.93
52-week low 311.34
50-day moving average 314.17
200-day moving average 314.19

Share statistics

Avg vol (3-month) 33.65M
Avg vol (10-day) 33.22M
Shares outstanding 5452.78M
Implied shares outstanding 6459.21M
Float 8169.45M
% held by insiders 162.22%
% held by institutions 12.23%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.34
Forward annual dividend yield 42.27%
Trailing annual dividend rate 30.34
Trailing annual dividend yield 32.27%
5-year average dividend yield 42.01
Payout ratio 433.84%
Dividend date 3N/A
Ex-dividend date 414 June 2023
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 10.27%
Operating margin (ttm)17.52%

Management effectiveness

Return on assets (ttm)3.81%
Return on equity (ttm)8.49%

Income statement

Revenue (ttm)4.36B
Revenue per share (ttm)9.64
Quarterly revenue growth (yoy)-5.60%
Gross profit (ttm)N/A
EBITDA 641.35M
Net income avi to common (ttm)448.19M
Diluted EPS (ttm)0.99
Quarterly earnings growth (yoy)16.60%

Balance sheet

Total cash (mrq)2.7B
Total cash per share (mrq)5.98
Total debt (mrq)151.39M
Total debt/equity (mrq)2.70%
Current ratio (mrq)3.74
Book value per share (mrq)12.36

Cash flow statement

Operating cash flow (ttm)396.49M
Levered free cash flow (ttm)613.06M